The Pershing Square Sohn Cancer Research Alliance today announced the seven winners of the 2018 Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early-career cancer research scientists in the New York City-area.
Miami Cancer Institute, part of Baptist Health South Florida, a member of the Memorial Sloan Kettering Cancer Alliance, said it has begun treating patients with MR image-guided radiation therapy with the installation of the ViewRay MRIdian Linac.
Amy Trentham-DietzRandy KimpleNihal AhmadAmy Trentham-Dietz was named associate director for population sciences at the University of Wisconsin Carbone Cancer Center.
Rusk Rehabilitation at NYU Langone Health has opened a specialized program to address the rehabilitative needs of individuals with cancer, with a principal goal of helping them re-establish optimal function during and following treatment.
The latest Annual Report to the Nation on the Status of Cancer finds that overall cancer death rates continue to decline in men, women, and children in the United States in all major racial and ethnic groups.
After six months of listening and observing the functioning of MD Anderson Cancer Center, Peter Pisters announced changes in the cancer center's organizational chart.
FDA has approved Darzalex (daratumumab) in combination with Velcade (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
The European Medicines Agency has approved LYNPARZA (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.
FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel and carboplatin, for the initial treatment of people with metastatic non-squamous non-small cell lung cancer.
Eli Lilly and Co. and ARMO BioSciences Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.
